arGEN-X is formerly owned by Omnes Capital, through Omnes Co-Investment, since 2009.

When did Omnes Capital acquire arGEN-X?

Omnes Capital acquired arGEN-X in 2009 and exited after 8 years.

Has arGEN-X been sold?

Yes. arGEN-X was exited in 2017.

Biotech·

Netherlands·Exited 2017·Held 8yr

arGEN-X is a biotech company, headquartered in Netherlands.

Entry

2009

Hold

8yr

Exit

2017

Est. EV

–

Investor

HQNetherlands

SectorBiotech

Biotech developing antibody therapies. IPO Euronext 2014, fully exited 2017.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

6 portfolio peers in Omnes Co-Investment

6 comparable biotech deals from other GPs

Exit details: type, year, MOIC (buyer on Pro)

Already a member? Sign in

Data refreshed weekly · Sourced from public filings